Yanyan Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanyan Xiao has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hao Lu
Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
3 shared publications - Chi Chen
Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine , 528, Zhangheng Road, Shanghai 201203
2 shared publications Qi Chen
Department of Endocrinology and Metabolism, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publicationsBilikezi Abuduhelili
Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication- Bilikezi Abuduhelili
Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication - Caifang Sun
Department of Endocrinology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
1 shared publication
Latest Publications
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 23, 1-10
Age at Menarche is Linked to Adiposity and Body Fat Distribution: A Nationally Representative Study
Objective: The study comprehensively examined the association between age at menarche and multiple indicators of body adiposity among U.S. women representative of the national population. Methods: Data from 5,480 women participating in the National Health and Nutrition Examination Survey 2011-2018 were analyzed. Age at menarche was obtained via self-reporting. Qualified technicians measured body mass index and waist circumference. The total and regional body fat were assessed using dual-energy X-ray absorptiometry. Results: The median age at menarche was 13 years. After adjustment for sociodemographic, lifestyle, reproductive and metabolic factors, early menarche (≤11 years) was significantly associated with an elevated risk of general obesity (OR 1.837, 95% CI 1.462-2.308), abdominal obesity (OR 1.576, 95% CI 1.229-2.022), and excess body fat (OR 1.822-95% CI 1.394, 2.381) compared with normal menarche (12-14 years). Furthermore, age at menarche was negatively associated with the android-to-gynoid fat ratio (β = -0.008, 95% CI: -0.012 to -0.004) and positively associated with the leg-to-trunk fat ratio (β = 0.007, 95% CI: 0.001 to 0.013) after multivariate adjustment. Discussion: The study’s findings suggest that earlier menarcheal onset is associated with increased adiposity and an unfavorable body fat distribution in adulthood. These results support the importance of reproductive factors in obesity pathophysiology and highlight the need for early preventive interventions among girls experiencing early menarche. Conclusion: Earlier menarche is associated with an elevated risk of adiposity and unfavorable body fat distribution among U.S. women. Prospective longitudinal studies are warranted to further assess causality and to explore the mechanisms involved.
- 7 September 2026
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 23, 1-10
Age at Menarche is Linked to Adiposity and Body Fat Distribution: A Nationally Representative Study
Objective: The study comprehensively examined the association between age at menarche and multiple indicators of body adiposity among U.S. women representative of the national population. Methods: Data from 5,480 women participating in the National Health and Nutrition Examination Survey 2011-2018 were analyzed. Age at menarche was obtained via self-reporting. Qualified technicians measured body mass index and waist circumference. The total and regional body fat were assessed using dual-energy X-ray absorptiometry. Results: The median age at menarche was 13 years. After adjustment for sociodemographic, lifestyle, reproductive and metabolic factors, early menarche (≤11 years) was significantly associated with an elevated risk of general obesity (OR 1.837, 95% CI 1.462-2.308), abdominal obesity (OR 1.576, 95% CI 1.229-2.022), and excess body fat (OR 1.822-95% CI 1.394, 2.381) compared with normal menarche (12-14 years). Furthermore, age at menarche was negatively associated with the android-to-gynoid fat ratio (β = -0.008, 95% CI: -0.012 to -0.004) and positively associated with the leg-to-trunk fat ratio (β = 0.007, 95% CI: 0.001 to 0.013) after multivariate adjustment. Discussion: The study’s findings suggest that earlier menarcheal onset is associated with increased adiposity and an unfavorable body fat distribution in adulthood. These results support the importance of reproductive factors in obesity pathophysiology and highlight the need for early preventive interventions among girls experiencing early menarche. Conclusion: Earlier menarche is associated with an elevated risk of adiposity and unfavorable body fat distribution among U.S. women. Prospective longitudinal studies are warranted to further assess causality and to explore the mechanisms involved.
- Open Access
- 1 January 2026
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 19, 1-16
Salvianolic Acids and Their Pharmacological Promise in Kidney Diseases: A Narrative Review
Kidney disease is a major public health challenge, affecting millions of people worldwide. Conventional treatments often produce suboptimal outcomes and are associated with various adverse effects. Traditional Chinese Medicine has shown promising therapeutic potential, offering distinct advantages over conventional therapies for preventing and treating kidney diseases. Salvianolic acids, the principal bioactive constituents of Salvia miltiorrhiza, are widely used in the management of renal disorders. However, no dedicated review has systematically synthesized pharmacological evidence across different models of kidney disease. To advance both basic research and clinical applications, this review summarizes current knowledge on the therapeutic effects of salvianolic acids in acute kidney injury, diabetic kidney disease, and nephrotic syndrome. Their renoprotective actions arise from the modulation of multiple pathological processes, including inflammation, oxidative stress, apoptosis, mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy dysregulation. Collectively, salvianolic acids hold promise as potential therapeutic agents for kidney diseases. Further studies are needed to confirm these molecular mechanisms and identify specific targets. Additionally, large-scale, long-term, multicenter clinical trials are crucial to evaluate the efficacy and safety of salvianolic acids in treating kidney diseases.
- 1 January 2026
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 19, 1-16
Open AccessSalvianolic Acids and Their Pharmacological Promise in Kidney Diseases: A Narrative Review
Kidney disease is a major public health challenge, affecting millions of people worldwide. Conventional treatments often produce suboptimal outcomes and are associated with various adverse effects. Traditional Chinese Medicine has shown promising therapeutic potential, offering distinct advantages over conventional therapies for preventing and treating kidney diseases. Salvianolic acids, the principal bioactive constituents of Salvia miltiorrhiza, are widely used in the management of renal disorders. However, no dedicated review has systematically synthesized pharmacological evidence across different models of kidney disease. To advance both basic research and clinical applications, this review summarizes current knowledge on the therapeutic effects of salvianolic acids in acute kidney injury, diabetic kidney disease, and nephrotic syndrome. Their renoprotective actions arise from the modulation of multiple pathological processes, including inflammation, oxidative stress, apoptosis, mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy dysregulation. Collectively, salvianolic acids hold promise as potential therapeutic agents for kidney diseases. Further studies are needed to confirm these molecular mechanisms and identify specific targets. Additionally, large-scale, long-term, multicenter clinical trials are crucial to evaluate the efficacy and safety of salvianolic acids in treating kidney diseases.